Dr Sangeetha Ramanujam
/content/dam/genesiscare/headshots/au-doctor-headshots/au-headshot-doctor-sngeetha-ramanujam-cropped.jpeg

Dr Sangeetha Ramanujam

Dr Sangeetha Ramanujam
Sangeetha
Ramanujam
MBBS, MRCP (UK), FRACP, MClinTR, Medical Oncologist

Languages spoken

English, Tamil, Kannada, Hindi

Overview

Clinical interest in gastrointestinal and genitourinary malignancies.

Dr. Sangeetha Ramanujam has over ten years of professional experience in managing cancer patients which includes fellowship training in gastrointestinal malignancies and melanoma from renowned Australian centres. Her key interests are in gastrointestinal and genitourinary malignancies.

She is passionate about provision of comprehensive cancer care to regional patients, closer to patients hometown. Here she treats patients with all solid organ cancers and regularly attends breast, lung, gastrointestinal, urology and melanoma multidisciplinary team meetings (MDT) across the Riverina Cancer Care and Griffith Oncology network. Sangeetha has completed her Masters in Clinical Trials and Research through the University of Sydney and is involved in publishing real world research.

Research interests

Stephanie's research interests are in gastrointestinal (GI) cancer, in particular colorectal cancer. Her PhD was on the investigation of 'Biomarker changes during chemoradiation in locally advanced rectal cancer'. She is part of the medical oncology group at the Ingham Institute for Applied Medical Research. Current research projects include the investigation of circulating tumour RNA in rectal cancer, biomarker investigation to predict treatment response and prognosis in colorectal cancer, and clinical outcomes in colorectal cancer based on data from a national registry. 

Professional memberships

  • RACP
  • MOGA
  • AGITG
  • TOGA
  • ESMO
  • ASCO

Publications

  • Sangeetha Ramanujam, Dirk Schadendorf, Georgina V. Long, Systemic therapies for melanoma brain metastases: which drug for whom and when? Chin Clin Oncol 2015; 4(2):25
  • A.M Menzies, D.B. Johnson, S. Ramanujam and G.V Long, Anti-PD1 therapy in patients with advanced melanoma and pre-existing autoimmune disorders or major toxicity with ipilimumab, Ann Oncol (2016), doi:10.1093/annonc/mdw443, published September 2016